Outcomes of Direct-Acting Antivirals Versus Interferon-Based Therapy in Chronic Hepatitis C Infection

This systematic review evaluates the outcomes of direct-acting antivirals (DAAs) compared to interferon-based therapies in patients with chronic hepatitis C infection. DAAs consistently demonstrate higher sustained virologic response (SVR) rates and better safety profiles across various patient populations, including those with cirrhosis and treatment-experienced individuals. The studies included highlight the superior efficacy of DAAs, with fewer adverse events such as anemia and fatigue, making them more tolerable and suitable for long-term treatment. These findings reinforce the clinical importance of DAAs as the standard of care for managing hepatitis C virus (HCV), particularly in special populations. Although interferon-based therapies remain relevant in resource-limited settings, this review emphasizes the need for broader access to DAAs to improve global health outcomes and reduce HCV-related morbidity and mortality.